Clinical Study of BCG Vaccine for Intradermal Injection
Condition: Tuberculosis Interventions: Biological: BCG vaccine 1（0.025mg/0.1ml/person）; Biological: BCG vaccine 2 （0.05mg/0.1ml/person）; Biological: BCG vaccine 3（0.075mg/0.1ml/person）; Biological: BCG vaccine 4 （0.075mg/0.1ml/person）; Biological: Placebo of BCG vaccine （0.1ml/person） Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition: Human Immunodeficiency Virus Interventions: Biological: M72/AS01E Mycobacterium tuberculosis vaccine; Biological: Placebo Sponsor: Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials
TB Screening Improves Preventive Therapy Uptake
Conditions: Tuberculosis; Latent Tuberculosis; Tuberculosis Prevention; HIV Intervention: Device: CRP, point-of-care assay Sponsors: University of California, San Francisco; Makerere University; Infectious Diseases Research Collaboration, Uganda; Johns Hopkins University; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition: Human Immunodeficiency Virus Interventions: Biological: M72/AS01E Mycobacterium tuberculosis vaccine; Biological: Placebo Sponsor: Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials
TB Screening Improves Preventive Therapy Uptake
Conditions: Tuberculosis; Latent Tuberculosis; Tuberculosis Prevention; HIV Intervention: Device: CRP, point-of-care assay Sponsors: University of California, San Francisco; Makerere University; Infectious Diseases Research Collaboration, Uganda; Johns Hopkins University; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition: Human Immunodeficiency Virus Interventions: Biological: M72/AS01E Mycobacterium tuberculosis vaccine; Biological: Placebo Sponsor: Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials
TB Screening Improves Preventive Therapy Uptake
Conditions: Tuberculosis; Latent Tuberculosis; Tuberculosis Prevention; HIV Intervention: Device: CRP, point-of-care assay Sponsors: University of California, San Francisco; Makerere University; Infectious Diseases Research Collaboration, Uganda; Johns Hopkins University; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition: Human Immunodeficiency Virus Interventions: Biological: M72/AS01E Mycobacterium tuberculosis vaccine; Biological: Placebo Sponsor: Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials
TB Screening Improves Preventive Therapy Uptake
Conditions: Tuberculosis; Latent Tuberculosis; Tuberculosis Prevention; HIV Intervention: Device: CRP, point-of-care assay Sponsors: University of California, San Francisco; Makerere University; Infectious Diseases Research Collaboration, Uganda; Johns Hopkins University; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition: Human Immunodeficiency Virus Interventions: Biological: M72/AS01E Mycobacterium tuberculosis vaccine; Biological: Placebo Sponsor: Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials
TB Screening Improves Preventive Therapy Uptake
Conditions: Tuberculosis; Latent Tuberculosis; Tuberculosis Prevention; HIV Intervention: Device: CRP, point-of-care assay Sponsors: University of California, San Francisco; Makerere University; Infectious Diseases Research Collaboration, Uganda; Johns Hopkins University; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition: Human Immunodeficiency Virus Interventions: Biological: M72/AS01E Mycobacterium tuberculosis vaccine; Biological: Placebo Sponsor: Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials
TB Screening Improves Preventive Therapy Uptake
Conditions: Tuberculosis; Latent Tuberculosis; Tuberculosis Prevention; HIV Intervention: Device: CRP, point-of-care assay Sponsors: University of California, San Francisco; Makerere University; Infectious Diseases Research Collaboration, Uganda; Johns Hopkins University; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition: Human Immunodeficiency Virus Interventions: Biological: M72/AS01E Mycobacterium tuberculosis vaccine; Biological: Placebo Sponsor: Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 20, 2020 Category: Research Source Type: clinical trials
TB Screening Improves Preventive Therapy Uptake
Conditions: Tuberculosis; Latent Tuberculosis; Tuberculosis Prevention; HIV Intervention: Device: CRP, point-of-care assay Sponsors: University of California, San Francisco; Makerere University; Infectious Diseases Research Collaboration, Uganda; Johns Hopkins University; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 19, 2020 Category: Research Source Type: clinical trials
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition: Human Immunodeficiency Virus Interventions: Biological: M72/AS01E Mycobacterium tuberculosis vaccine; Biological: Placebo Sponsor: Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 19, 2020 Category: Research Source Type: clinical trials
Microneedles for Diagnosis of LTBI
Condition: Latent Tuberculosis Intervention: Diagnostic Test: TST vs PPD microneedle test Sponsors: The HIV Netherlands Australia Thailand Research Collaboration; National Nanotechnology Center (NANOTEC), The National Science and Technology Development Agency (NSTDA) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials
Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark
AbstractObjectives: The Bacille Calmette-Gu érin (BCG) vaccine against tuberculosis is associated with non- specific protective effects against other infections, and significant reductions in all-cause morbidity and mortality have been reported. We aim to test whether BCG vaccination may reduce susceptibility to and/or the severity of COVID- 19 and other infectious diseases in health care workers (HCW) and thus prevent work absenteeism.The primary objective is to reduce absenteeism due to illness among HCW during the COVID-19 pandemic. The secondary objectives are to reduce the number of HCW that are infected with S...
Source: Trials - September 17, 2020 Category: Research Source Type: clinical trials
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Conditions: Infections and Infestations; Pulmonary Tuberculosis Interventions: Drug: Delpazolid; Drug: Bedaquiline, Delamanid, Moxifloxacin Sponsors: LegoChem Biosciences, Inc; Ludwig-Maximilians - University of Munich; Radboud University; University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Conditions: Tuberculosis; Hiv Interventions: Drug: Rifapentine daily; Drug: Rifapentine weekly Sponsors: Yale University; Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Conditions: Infections and Infestations; Pulmonary Tuberculosis Interventions: Drug: Delpazolid; Drug: Bedaquiline, Delamanid, Moxifloxacin Sponsors: LegoChem Biosciences, Inc; Ludwig-Maximilians - University of Munich; Radboud University; University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Conditions: Tuberculosis; Hiv Interventions: Drug: Rifapentine daily; Drug: Rifapentine weekly Sponsors: Yale University; Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Conditions: Infections and Infestations; Pulmonary Tuberculosis Interventions: Drug: Delpazolid; Drug: Bedaquiline, Delamanid, Moxifloxacin Sponsors: LegoChem Biosciences, Inc; Ludwig-Maximilians - University of Munich; Radboud University; University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Conditions: Tuberculosis; Hiv Interventions: Drug: Rifapentine daily; Drug: Rifapentine weekly Sponsors: Yale University; Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Conditions: Infections and Infestations; Pulmonary Tuberculosis Interventions: Drug: Delpazolid; Drug: Bedaquiline, Delamanid, Moxifloxacin Sponsors: LegoChem Biosciences, Inc; Ludwig-Maximilians - University of Munich; Radboud University; University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Conditions: Tuberculosis; Hiv Interventions: Drug: Rifapentine daily; Drug: Rifapentine weekly Sponsors: Yale University; Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Conditions: Infections and Infestations; Pulmonary Tuberculosis Interventions: Drug: Delpazolid; Drug: Bedaquiline, Delamanid, Moxifloxacin Sponsors: LegoChem Biosciences, Inc; Ludwig-Maximilians - University of Munich; Radboud University; University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Conditions: Tuberculosis; Hiv Interventions: Drug: Rifapentine daily; Drug: Rifapentine weekly Sponsors: Yale University; Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Conditions: Infections and Infestations; Pulmonary Tuberculosis Interventions: Drug: Delpazolid; Drug: Bedaquiline, Delamanid, Moxifloxacin Sponsors: LegoChem Biosciences, Inc; Ludwig-Maximilians - University of Munich; Radboud University; University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials
Influence of Filarial Infections on Tuberculosis Disease and Tuberculosis Vaccination in Cameroon
Condition: Tuberculosis Intervention: Drug: TB treatment according to national guidelines Sponsor: University Hospital, Bonn Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2020 Category: Research Source Type: clinical trials
